Skip to main content
Smart Investors Daily
WE

NASDAQ · WENAW

Anew Medical, Inc.

Healthcare · Biotechnology

$0.04

Down-$0.00 (-0.25%)

Updated Oct 10, 2026, 7:29 PM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
681.44K
P/E ratio
5.26
Dividend yield
0.00%
52-week range
— – —
Volume
4K
Avg. volume
0

Price performance · WENAW

WENAW price history

1M range · 0 trading sessions · Daily adjusted prices

WENAW does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest WENAW news

The latest Smart Investors Daily articles mentioning WENAW.

WENAW research

Overview

Company profile and research snapshot.

Company profile

Anew Medical, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. Anew Medical, Inc. is based in Omaha, Nebraska.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.